Abstract:Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is a tenacious pathogen that has latently infected one third of the world's population. However, conventional TB treatment regimens are no longer sufficient to tackle the growing threat of drug resistance, stimulating the development of innovative anti-tuberculosis agents, with special emphasis on new protein targets. The Mtb genome encodes ~4000 predicted proteins, among which many enzymes participate in various cellular metabolisms. For example, more than 200 proteins are involved in fatty acid biosynthesis, which assists in the construction of the cell envelope, and is closely related to the pathogenesis and resistance of mycobacteria. Here we review several essential enzymes responsible for fatty acid and nucleotide biosynthesis, cellular metabolism of lipids or amino acids, energy utilization, and metal uptake. These include InhA, MmpL3, MmaA4, PcaA, CmaA1, CmaA2, isocitrate lyases (ICLs), pantothenate synthase (PS), Lysine-ε amino transferase (LAT), LeuD, IdeR, KatG, Rv1098c, and PyrG. In addition, we summarize the role of the transcriptional regulator PhoP which may regulate the expression of more than 110 genes, and the essential biosynthesis enzyme glutamine synthetase (GlnA1). All these enzymes are either validated drug targets or promising target candidates, with drugs targeting ICLs and LAT expected to solve the problem of persistent TB infection. To better understand how anti-tuberculosis drugs act on these proteins, their structures and the structure-based drug/inhibitor designs are discussed. Overall, this investigation should provide guidance and support for current and future pharmaceutical development efforts against mycobacterial pathogenesis.

The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective

Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis

Overcoming Mycobacterium Tuberculosis Through Small Molecule Inhibitors to Break Down Cell Wall Synthesis

Structural Biology and Inhibition of the Mtb Cell Wall Glycoconjugates Biosynthesis on the Membrane

The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Approaches for targeting the mycobactin biosynthesis pathway for novel anti-tubercular drug discovery: where we stand

Mycobacterial FtsZ and inhibitors: a promising target for the anti-tubercular drug development

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Chemical Synthesis of Cell Wall Constituents of Mycobacterium tuberculosis

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport

DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery

Anti-mycobacterial natural products and mechanisms of action

New structural classes of antituberculosis agents

Protein Targets for Structure-Based Anti-Mycobacterium Tuberculosis Drug Discovery

Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery

Assembling of the Mycobacterium Tuberculosis Cell Wall Core

Mycobacterial Targets for Thiourea Derivatives: Opportunities for Virtual Screening in Tuberculosis Drug Discovery

Mycobacterium tuberculosis F-ATP Synthase Inhibitors and Targets

Vitamin in the Crosshairs: Targeting Pantothenate and Coenzyme A Biosynthesis for New Antituberculosis Agents

Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens